ADIA Nutrition names Dawn Bell as chief revenue officer

ADIA Nutrition Inc. (OTCQB: ADIA) announced the appointment of Dawn Bell as Chief Revenue Officer through its subsidiary ADIA Labs, according to a press release statement.

Bell brings over 15 years of experience as a sales strategist in the medical device and pharmaceutical industries. In her new role, she will focus on strengthening revenue for ADIA Nutrition and its laboratory operations while partnering with doctors and clinics to integrate the company's regenerative therapies and diagnostic services.

The appointment coincides with preparations for Adia Med of Winter Park to launch its first Institutional Review Board-approved clinical study focused on autism.

"She brings the experience and vision needed to take our growth to the next level," said Larry Powalisz, CEO of ADIA Nutrition. "Dawn's real impact will be in making everyone successful-equipping our physician and clinic partners with the tools, training, and support to grow their practices."

ADIA Nutrition, based in Winter Park, Florida, operates in regenerative medicine through its stem cell and regenerative products including AdiaVita and AdiaLink. The company generates revenue through service fees, product sales, equity stakes, and insurance billing for healthcare treatments.

The company operates Adia Med clinics nationwide, specializing in orthopedic, pain management, and wound repair services. These clinics offer stem cell therapies, platelet-rich plasma treatments, therapeutic plasma exchange, and autologous hematopoietic stem cell transplantation.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Devonian Health Group plans NYSE American listing under DHGR
• Peraso CFO James Sullivan resigns effective October 2026